Honorees include Brazil’s President Lula and 10 leaders working to improve health and nutrition in their communities NEW YORK, Sept. 24, 2024 /PRNewswire/ — At its event, Goalkeepers 2024: Recipe for Progress, the Bill & Melinda Gates Foundation honored remarkable leaders who are advancing the United Nations Sustainable Development Goals (Global Goals) with solutions to keep people […]
Category Archives: Pr Newswire
Global study shows that our mental state starts to decline after only two hours of continuous desk-based working, but just 15 minutes of exercise can help to reverse the effects ASICS enlists Brian Cox to take on the role of the world’s scariest boss to highlight the real threat to our mental health – the […]
SEOUL, Korea, Sept. 24, 2024 /PRNewswire/ — The 2024 HIMSS Asia Pacific Health Conference & Exhibition, one of the most influential digital health conferences in the APAC region, will be hosted for the first time in Seoul, Korea. The conference will take place from 1 – 4 October at the Coex Convention & Exhibition Center. The […]
HONG KONG, Sept. 24, 2024 /PRNewswire/ — iClick Interactive Asia Group Limited (“iClick” or the “Company”) (NASDAQ: ICLK), a renowned marketing cloud platform in China that empowers worldwide brands with full-stack consumer lifecycle solutions, today announced that it has closed its previously announced disposal of its enterprise solutions business in mainland China in accordance with […]
Provides a comprehensive roadmap that bridges education and climate goals and outlines key recommendations to drive meaningful action at the climate-education nexus DUBAI, UAE, Sept. 24, 2024 /PRNewswire/ — Dubai Cares has launched its latest report, “Rewiring Education: The Climate- Education Nexus,” advocating for integrating education and climate action, during the 79th United Nations General […]
Pr Newswire
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
23
Sep
Sep
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing […]
Pr Newswire
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
23
Sep
Sep
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc analyses from Study 403 including the prespecified patient population with MDD or bipolar depression with mixed features who also had anxious distress NEW YORK, […]
Pr Newswire
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
23
Sep
Sep
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET – The European Microbiome Innovation for Health (EMIH) association today announced an agreement between the Microbiome Therapeutics Innovation Group (MTIG) and EMIH for a collaboration to advance microbiome drug development, explore synergies between international regulators, and convene cross-continental […]
Pr Newswire
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis
23
Sep
Sep
FORT LEE, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, a PD-1 inhibitor, as a first-line […]
23
Sep
Sep
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will […]